Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.
Globally, drugmakers are expected to increase second-quarter earnings per share by 2%, after they rose 17% in the first quarter, according to Cowen & Co.
Pfizer, which has released early data on its vaccine candidate being developed with German biotech BioNTech SE , will kick off the week of drugmaker earnings on Tuesday morning. Gilead’s antiviral treatment, remdesivir, has become a key weapon for many countries after the intravenously administered medicine helped shorten hospital recovery times in a U.S. trial.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Dow rises 100 points as Apple leads tech higherU.S. stocks traded mostly flat to start the week as investors braced for a big week of corporate earnings and more Covid stimulus talks.
Weiterlesen »
Moderna shares jump after U.S. ups funding for coronavirus vaccine by $472 millionModerna shares jump, after the biotech company announced it received an additional $472 million from the U.S. government to support the development of its potential coronavirus vaccine. $MRNA
Weiterlesen »
US stocks rise as tech trades higher, investors await stimulus bill | Markets InsiderUS stocks rose on Monday as investors looked to major earnings on deck this week and awaited the release of the GOP's coronavirus stimulus plan....
Weiterlesen »
Moderna gets further $472 million U.S. award for coronavirus vaccine developmentModerna Inc said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.
Weiterlesen »
Moderna gets further $472 million U.S. award for coronavirus vaccine developmentModerna said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority to support the development of its novel coronavirus vaccine.
Weiterlesen »